Clinician Guide to CAR T-Cell Therapy for R/R NHL
In 2017, the first CAR T-cell therapy was approved for adults with R/R LBCL.[2] Patients who may be eligible for CAR T-cell therapy should be referred to a CAR T-cell therapy center for evaluation as soon as possible.[1],[5]
CAR T-Cell Therapy Center Contacts
Memorial Sloan Kettering Cellular Therapy Service
UC San Diego Health
Moffitt Cancer Center
FDA-Approved CAR T-cell Therapies for R/R NHL
As of July 30, 2026[2]
Search terms are recorded for usage analytics. Do not enter patient information.
- •LBCL, including DLBCL not otherwise specified, high grade BCL, primary mediastinal LBCL, and FL grade 3B, that is R/R to 1L chemoimmunotherapy, R/R to 1L chemoimmunotherapy where patients are not eligible for HSCT due to comorbidities or age, or R/R after ≥2 lines of systemic therapy
- •R/R CLL or SLL who have received ≥2 lines therapy, including a BTK inhibitor and BCL-2 inhibitor*
- •R/R FL who have received ≥2 prior lines of systemic therapy
- •R/R MCL after ≥2 lines of systemic therapy, including a BTK inhibitor
- •R/R MZL after ≥2 lines of systemic therapy
- •LBCL that is R/R to 1L chemoimmunotherapy
- •R/R LBCL after ≥2 lines of systemic therapy for DLBCL not otherwise specified, primary mediastinal LBCL, high grade B-cell lymphoma, and DLBCL arising from FL
- •R/R FL after ≥2 lines of systemic therapy*
- •R/R MCL
- •R/R LBCL after ≥2 lines of systemic therapy, including DLBCL not otherwise specified, high grade BCL, and DLBCL arising from FL
- •R/R FL after ≥2 of systemic therapy*
* Approved under accelerated approval based on response rate and duration of response. Continued approval may be contingent upon verification of clinical benefit in confirmatory trial(s).[2]
Considerations When Determining Patient Eligibility
Provided by Integritas Communications. BCL, B-cell lymphoma; BTK, Bruton tyrosine kinase; CAR, chimeric antigen receptor; CD19, cluster of differentiation 19; CLL, chronic lymphocytic leukemia; CNS, central nervous system; DLBCL, diffuse LBCL; FDA, US Food and Drug Administration; FL, follicular lymphoma; HSCT, hematopoietic stem cell transplantation; LBCL, large BCL; MCL, mantle cell lymphoma; MSK, Memorial Sloan Kettering; UC, University of California; NHL, non-Hodgkin lymphoma; MZL, marginal zone lymphoma; R/R, relapsed/refractory; SLL, small lymphocytic lymphoma.
References
- 1.Memorial Sloan Kettering, UC San Diego Health, and Moffitt Cancer Center – CAR T-cell therapy program contacts
- 2.FDA – Approved Cellular and Gene Therapy Products
- 3.NCCN Clinical Practice Guidelines in Oncology – B-Cell Lymphomas
- 4.FDA – Boxed Warning for CRS and Neurologic Toxicities (CAR T-cell Therapies)
- 5.American Society for Transplantation and Cellular Therapy (ASTCT) – Referral Guidelines